Dragonfly's TriNKET compounds are designed to activate and direct NK and cytotoxic T cell killing against cancer cells. The platform has also attracted partnerships from other pharma groups ...

so need to be activated before they attack cancer cells that present antigens. NK cells are part of the innate immune system, a first line of defense that doesn't need to be primed into action.

NK cells have been shown to play a pivotal role in HCC, with multiple trials underway assessing the effectiveness of NK cell–based treatment in the cancer type, which carries a poor prognosis ...

ImmunityBio has announced the commencement of a Phase I clinical trial evaluating its CD19 targeted high-affinity natural ...